Abstract

To estimate the cost-effectiveness of secukinumab compared with other available biologic therapies in the treatment of active ankylosing spondylitis (AS), under the Brazilian Unified Health System (SUS) perspective.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
P186 Secukinumab effectiveness and safety in patients with active psoriatic arthritis or ankylosing spondylitis: interim analysis of an observational study in the real-world setting
Karl Gaffney ... Petros Sfikakis
Rheumatology (Oxford, England) | VOL. 60
Karl Gaffney, et. al.Karl Gaffney ... Petros Sfikakis
25 Apr 2021
EE240 Estimating the COVID-19 Cost-of-Illness Associated with Comorbidities in a Brazilian Public Hospital
La Oliveira ... A Wiens
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 25
La Oliveira, et. al.La Oliveira ... A Wiens
25 Jun 2022
THU0371 Therapy modifications in patients with ankylosing spondylitis treated with a biologic in the united states – descriptive analyses from an administrative claims database
Ja Walsh ... B Chastek
Annals of the Rheumatic Diseases | VOL. 76
Ja Walsh, et. al.Ja Walsh ... B Chastek
01 Jun 2017
POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
D Van Der Heijde ... X Zeng
Annals of the Rheumatic Diseases | VOL. 81
D Van Der Heijde, et. al.D Van Der Heijde ... X Zeng
23 May 2022
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers